Vyvgart
Active Ingredient(s): Efgartigimod AlfaFDA Approved: * December 17, 2021
Pharm Company: * ARGENX BV
Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis.[1][2] The most common side effects include respiratory tract infections, headache, and urinary tract infections.[2] Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication.[2] It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (Ig... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.